Adhera Therapeutics Inc
ATRX - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$722
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $722.00 |
|---|---|
| Enterprise Value | $10.90 Million |
| Earnings per Share | $-1.18 |
| Beta | 9.09 |
| Outstanding Shares | 4,304,000 |
Return
| Return on Equity | 17.05% |
|---|---|
| Return on Assets | -10178.34% |
| Return on Invested Capital | 3.56% |
Valuation & Multiples
| P/E Ratio | 0 |
|---|---|
| PEG | 0 |
| Price to Sales | - |
| Price to Book Ratio | -0.0 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -11.62 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 1 |
| Debt to Equity | -0.42 |
Revenue Sources
No data
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Adhera Therapeutics Inc
2 employees
CEO: David A. Battat
Adhera Therapeutics, Inc., a biotech company, focuses on the discovery, development, and commercialization of small molecule drugs. The company is developing MLR-1019 for the treatment of Parkinson’s disease; and MLR -1023 to treat Type ...